Microbial protein restores vision in blind mice
Using gene therapy, scientists from NIBR's Friedrich Miescher Institute for Biomedical Research (FMI) reactivate vision in retinitis pigmentosa using an archaebacterial protein.

Rare Disease Drug Discovery Approach Recognized
NIBR Researchers Approach Rare Disease as Entryways to Broader Cures.

From Shanghai to Boston, NIBR Volunteers
NIBR Associates roll up their sleeves for Community Partnership Day.

Advice to Chemists - Be Innovative
Regional chemists gathered at NIBR Cambridge recently to examine career prospects in this US economy. The advice was clear. Be open to innovation.

Access NIBR Published Research With OAK
New and archived Peer-reviewed research papers published by our scientists are now easily accessed through NIBR’s public database on OAK, Open Access to Knowledge.

Proof-of-Concept: record productivity at Novartis R&D
Guided by a proven research strategy, Novartis scientists delivered more hope for patients with a record twelve positive Proof-of-Concept (PoC) compounds in 2009.

A lab for our future
Scientists, designers, technology experts, and lab associates unite to shape state-of-the-art laboratory environments and a new culture of innovation at Novartis research.

NIBR Horsham, Basel and Cambridge Among Best Places to Work for Postdocs
"Scientist’s" Survey of Postdoctoral Fellows named NIBR Horsham their favorite place to work, with the Institute’s Basel and Cambridge campuses among the top five in the world. With an emphasis on early drug discovery, NIBR researchers and their Fellows are engaged in path-breaking, career-making science.

Novartis scientists identify new allosteric inhibitors for Bcr-Abl
New Nature paper: Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.

Proof in pathways: Ilaris brings new hope to patients ›
With a focus on patient need and the molecular cause of several related diseases, Novartis scientists discovered and rapidly developed Ilaris® – a new biological therapy recently approved for a rare but serious group of auto-inflammatory disorders.

Netpals bring science to elementary students in Cambridge, USA ›
Exposing kids to the wonders of science inside the research buildings they walk by every day is the driving force behind the Novartis Netpals program.

Productivity on the rise in Research and Development ›
An unwavering focus on cutting-edge science and the unmet needs of patients delivered further productivity gains for Novartis R&D during 2008.

Tackling Respiratory Diseases ›
NIBR scientist is breaking the cycle in Cystic Fibrosis.

Blocking Sodium Channels ›
NIBR Scientists are helping patients with Cystic fibrosis breathe easier.

More Than Skin Deep ›
An antibody drug could change the way we treat psoriasis.

Muckle-Wells and Beyond ›
Learn how we are treating patients who are in desperate need of options and finding new treatments for similar diseases.